Haleon (LON:HLN) Insider Blathnaid Bergin Buys 7,670 Shares of Stock

Key Points

• Haleon insider Blathnaid Bergin bought 7,670 shares at GBX 324 each, totaling approximately £24,851.
• Haleon approved a £500 million share buyback program, allowing repurchases of up to 1.8% of outstanding shares.
• Analysts’ consensus rating is “Hold” with a GBX 356 target price, while shares recently opened at GBX 318.25 and remain near their one-year low.

Haleon plc (LON:HLN - Get Free Report) insider Blathnaid Bergin acquired 7,670 shares of the company's stock in a transaction dated Friday, October 30th. The shares were acquired at an average cost of GBX 324 per share, with a total value of £24,850.80.

Haleon Stock Performance

Shares of HLN stock opened at GBX 318.25 on Monday. The firm has a market capitalization of £27.99 billion, a price-to-earnings ratio of 17.58, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a 50 day moving average price of GBX 352.97 and a 200 day moving average price of GBX 360.40. Haleon plc has a one year low of GBX 310.50 and a one year high of GBX 433.60. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69.

Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. Sell-side analysts anticipate that Haleon plc will post 19.50 EPS for the current year.

Haleon declared that its Board of Directors has approved a stock repurchase program on Thursday, October 29th that authorizes the company to buy back £500 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 1.8% of its shares through open market purchases. Share buyback programs are generally an indication that the company's management believes its stock is undervalued.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Jefferies Financial Group restated a "buy" rating and issued a GBX 400 target price on shares of Haleon in a research report on Friday. Royal Bank Of Canada boosted their price objective on Haleon from GBX 370 to GBX 390 and gave the stock a "sector perform" rating in a research report on Tuesday, August 11th. Berenberg Bank cut their target price on Haleon from GBX 514 to GBX 365 and set a "buy" rating on the stock in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Haleon to a "hold" rating and cut their price objective for the company from GBX 320 to GBX 310 in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of GBX 356.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.